Welcome to our dedicated page for Amylyx Pharmaceuticals news (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals stock.
Amylyx Pharmaceuticals, Inc. develops investigational therapies for endocrine conditions and neurodegenerative diseases with high unmet medical need. News about AMLX centers on its clinical-stage pipeline, including avexitide, a GLP-1 receptor antagonist being evaluated for post-bariatric hypoglycemia, and additional programs such as AMX0035, AMX0114 and AMX0318.
Recurring company updates cover clinical trial progress, expanded access activity, development-candidate selections, program discontinuations, quarterly financial results and investor presentations. Amylyx news also reflects regulatory and commercial-readiness topics tied to investigational therapies, collaboration updates and capital-runway commentary typical of a biotechnology issuer advancing multiple development programs.
Summary not available.
Summary not available.
Amylyx Pharmaceuticals has appointed Masako Nakamura as General Manager and Head of International Markets for Asia Pacific and Latin America. With over 30 years of experience in the biopharmaceutical industry, she aims to enhance the global reach of AMX0035, also known as RELYVRIO in the U.S. and ALBRIOZA in Canada. The company is progressing with regulatory discussions in Europe following a strong commercial launch in the U.S. and Canada. Nakamura's leadership is expected to advance Amylyx's mission of delivering innovative therapies for amyotrophic lateral sclerosis (ALS) and addressing unmet needs in neurodegenerative diseases.
Amylyx Pharmaceuticals (NASDAQ: AMLX) has initiated dosing for the HELIOS study, a Phase 2 clinical trial of AMX0035 aimed at treating Wolfram syndrome (WS). The trial assesses the safety, tolerability, and various health functions related to WS. Initial preclinical data demonstrated the potential of AMX0035, showing improved WFS1 protein expression and delayed onset of diabetes in a mouse model. The findings were published in the Journal of Clinical Investigation Insight. The FDA granted orphan drug designation to AMX0035 in November 2020, enabling potential market exclusivity and financial incentives. Topline results from the HELIOS study are expected in 2024, addressing a critical unmet need in the WS community.
Amylyx Pharmaceuticals, Inc. (AMLX) announced participation in the 22nd Annual Needham Virtual Healthcare Conference. Co-CEOs Joshua Cohen and Justin Klee will present on April 18, 2023, at 12:45 PM ET. Investors can access a live webcast of the event through the company’s investor relations page, with a replay available for 90 days post-event.
Amylyx focuses on innovative treatments for neurodegenerative diseases, headquartered in Cambridge, Massachusetts, with operations in Canada and EMEA. For more details, visit the company's website.
Amylyx Pharmaceuticals reported full-year 2022 product revenue of $22.2 million, primarily from the launches of RELYVRIO® in the U.S. and ALBRIOZA™ in Canada. In Q4 2022, net product revenue was $21.9 million, while the net loss for the quarter increased to $42.7 million or $0.65 per share. The company announced the appointment of Karen Firestone to its Board of Directors and emphasized upcoming regulatory reviews in the EU. Despite strong launch engagement and ongoing Phase 3 trials, the company is aware of the challenges that lie ahead in expanding access for ALS patients.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced participation in two upcoming virtual investor conferences. Co-CEOs Joshua Cohen and Justin Klee will engage in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 8:40 am ET, followed by a presentation at the Stifel 2023 CNS Days on March 28, 2023, at 11:00 am ET. Both events will be accessible via live webcast on the company's investor relations page.
Amylyx focuses on developing innovative treatments for neurodegenerative diseases and is headquartered in Cambridge, Massachusetts, with operations in Canada and EMEA.
Amylyx Pharmaceuticals will release its fourth quarter and full year 2022 financial results on March 13, 2023, after U.S. market close. Senior management will host a conference call at 4:30 p.m. ET to discuss these results along with other company updates. Investors can access the call by dialing (833) 816-1395 in the U.S. or +1 (412) 317-0488 internationally, and a live audio webcast will be available in the Investor section of the company's website. The event will also be archived for 90 days.
Amylyx is focused on developing innovative treatments for the neurodegenerative disease community.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced that Co-CEOs Joshua Cohen and Justin Klee will participate in the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00am ET. The conference will be held virtually, and a live webcast of their presentation will be available in the 'Events' section of the company's website. A replay will be accessible for 90 days post-event. Amylyx is focused on developing innovative treatments for neurodegenerative diseases, with operations based in Cambridge, Massachusetts, and across Canada and EMEA.
Amylyx Pharmaceuticals has completed enrollment for the Phase 3 clinical trial, PHOENIX, evaluating AMX0035 for treating amyotrophic lateral sclerosis (ALS). This global, placebo-controlled study enrolled 664 participants and aims to assess the treatment's safety and efficacy over 48 weeks. Topline results are expected in 2024. The trial builds on positive outcomes from the prior Phase 2 CENTAUR trial, which demonstrated significant functional benefits and potential survival advantages. The European Medicines Agency is currently reviewing the marketing application for AMX0035, with a decision anticipated in early 2023.